Trials / Completed
CompletedNCT00811733
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Given the tolerability and efficacy of ofatumumab in follicular lymphoma and Chronic Lymphocytic Leukemia, and the need to improve therapy for patients with WM utilizing a non-myelosuppressive agent this phase II trial of ofatumumab is being initiated in patients with Waldenstrom's Macroglobulinemia (WM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ofatumumab | Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells. |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2011-06-01
- Completion
- 2014-02-01
- First posted
- 2008-12-19
- Last updated
- 2017-05-30
- Results posted
- 2012-04-30
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00811733. Inclusion in this directory is not an endorsement.